Entering text into the input field will update the search result below

AstraZeneca Can Prove To Be A Top Notch Investment Opportunity In 2017

Jul. 10, 2017 8:22 PM ETAstraZeneca PLC (AZN)ABBV, JNJ, LLY, PFE7 Comments
Healthcare on the Move profile picture
Healthcare on the Move


  • AstraZeneca expects to dominate the women’s cancer segment with PARP inhibitor, Lynparza.
  • Increasing demand for SGLT2 diabetes drug, Farxiga, will be major growth driver for AstraZeneca.
  • Once-a-week injectable diabetes therapy, Bydureon, will benefit from approval of auto-injector delivery mechanism.
  • Brilinta is inching closer to become a leader in the anti-clotting segment.
  • Delayed results from ARCTIC trial maybe an indication of negative results.

In my previous article, I discussed the scope of growth for AstraZeneca (NASDAQ:AZN) in non small lung cancer or NSCLC segment. But unlike many companies which overtly depend on a single opportunity, AstraZeneca has a broad portfolio with multiple innovative drugs, all set to make their mark in the market. The low business concentration risk has made the stock an attractive investment opportunity for retail investors with below average risk appetite.

In this article, I will explain promising aspects of AstraZeneca's product portfolio that go beyond NSCLC.

AstraZeneca plans to position PARP inhibitor, Lynparza, as a leading women's cancer therapy in 2017

Though Lynparza witnessed muted performance in USA in Q1 2017 due to intense competition in women's cancer segment, the drug is one of the major growth drivers for AstraZeneca, thanks to solid response in international markets. Already launched in around 31 countries, this late-stage BRCA-mutant ovarian cancer drug has been enjoying the fruits of improving penetration and awareness for diagnostic tests across the world. In Q1 2017, the drug also secured orphan drug designation in Japan, an important milestone considering that there are no drugs approved for BRCA-mutated ovarian cancer in the country. I have explained how PARP inhibitors work in another article on AbbVie (ABBV) in greater detail.

While the current approved indication of Lynparza is little too restrictive, AstraZeneca's extensive research program will unravel the real potential of this drug.

Positive results from SOLO-2 study and Study 19 have paved way for Lynparza's approval as second line maintenance therapy for BRCA-mutated ovarian cancer by Q3 2017. Further, data from the ongoing SOLO-1 trial which is expected in second half of 2017 can push Lynparza's use in first line maintenance indication for BRCA-mutated ovarian cancer, ahead of other PARP inhibitors such as AbbVie's veliparib and Pfizer's (

This article was written by

Healthcare on the Move profile picture
I am an MBA in finance and an engineering graduate. I have also completed the CFA certification.I am involved in international trade and have been passionately tracking global equity markets for more than 7 years. I mainly focus on spotting long-term value investments in biotechnology, pharmaceutical, hospital, and medical device sectors. In the last two years, I have also been studying cannabis and hemp sectors.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.